Side-by-side · Research reference
PTD-DBMvsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED10/40 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
PTD-DBM
Wnt Pathway Activator · Fusion Peptide
Topical / SQ · Study-dependent
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
PTD-DBM
Testagen
Primary target
CXXC5–Dishevelled protein-protein interaction
Testicular tissue; proposed nuclear DNA interaction
Pathway
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Not applicable — pathway derepression rather than receptor agonism
Unknown — no HPG axis data
Origin
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
PTD-DBM
Testagen
Wound healing protocol
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
—
Hair regeneration protocol
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
—
Co-administration
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
—
Human translation
No published human studies
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Frequency
—
Once daily or alternate days
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
04Side Effects & Safety
Parameter
PTD-DBM
Testagen
Reported adverse events
None reported in animal studies
—
Wnt pathway activation risks
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
—
Long-term safety
Unknown — no chronic dosing or human data
Unknown — no long-term studies
Delivery vehicle effects
HA-PG hydrogel well-tolerated in mice; human translation pending
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Absolute Contraindications
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Testagen
- ·Active testicular malignancy
Relative Contraindications
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
PTD-DBM
Testagen
1. Wound Healing Protocol (Animal Model)
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Hair Regeneration Protocol (Animal Model)
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Combination Therapy
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage & Handling
Not disclosed in available literature. Peptide stability and storage conditions not published.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Cycle protocol
—
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.